Qiagen N.V.
QGEN
Rank in Stocks
#2058
Qiagen N.V. provides sample to insight solutions that transform biological... Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
Share Price
$48.85
Last synced: 2026-10-20
Market Cap
$10.07B
Change (1 day)
4.96%
Change (1 year)
0.61%
Country
NL
Trade Qiagen N.V. (QGEN)
Category
Healthcare
Revenue for Qiagen N.V. (QGEN)
Revenue in Jun 2026 TTM: $2.10B
According to Qiagen N.V. latest financial reports the company's current revenue (TTM) is $2.10B. In 2024 the company made a revenue of $1.98B an increase over the revenue in the year 2023 that was $1.97B. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Qiagen N.V. from 2000 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| 2026 (TTM) | $2.10B | 0.50% |
| 2025 | $2.09B | 5.65% |
| 2024 | $1.98B | 0.66% |
| 2023 | $1.97B | -8.23% |
| 2022 | $2.14B | -4.89% |
| 2021 | $2.25B | 20.39% |
| 2020 | $1.87B | 22.53% |
| 2019 | $1.53B | 1.64% |
| 2018 | $1.50B | 5.95% |
| 2017 | $1.42B | 5.95% |
| 2016 | $1.34B | 4.45% |
| 2015 | $1.28B | -4.74% |
| 2014 | $1.34B | 3.29% |
| 2013 | $1.30B | 3.79% |
| 2012 | $1.25B | 7.24% |
| 2011 | $1.17B | 7.57% |
| 2010 | $1.09B | 7.69% |
| 2009 | $1.01B | 13.09% |
| 2008 | $892.98M | 37.43% |
| 2007 | $649.77M | 39.50% |
| 2006 | $465.78M | 16.91% |
| 2005 | $398.40M | 4.67% |
| 2004 | $380.63M | 8.32% |
| 2003 | $351.40M | 17.68% |
| 2002 | $298.61M | 13.21% |
| 2001 | $263.77M | 29.28% |
| 2000 | $204.03M | 0.00% |
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| $46.34B | 2,106.09% |
US
|
|
| $25.11B | 1,095.36% |
US
|
|
| $2.71B | 28.89% |
US
|
|
| - | - |
CN
|
|
| $7.37B | 250.99% |
US
|
